How have PRFX shares performed in 2024?

PainReform's stock was trading at $2.75 at the start of the year. Since then, PRFX stock has decreased by 68.1% and is now trading at $0.8780. View the best growth stocks for 2024 here .

When is PainReform's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PRFX earnings forecast .

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.80) earnings per share for the quarter, beating analysts' consensus estimates of ($4.30) by $2.50.

When did PainReform's stock split?

Shares of PainReform reverse split before market open on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS) , AbbVie (ABBV) , American Airlines Group (AAL) , Bank of America (BAC) , Bristol-Myers Squibb (BMY) , Clorox (CLX) , Cisco Systems (CSCO) , CVS Health (CVS) , Delta Air Lines (DAL) and DocuSign (DOCU) .

When did PainReform IPO?

PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

How do I buy shares of PainReform?

Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRFX

PainReform (PRFX) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free PRFX Stock Alerts

$0.88

-0.01 (-1.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.80
▼
$0.90
50-Day Range: $0.81
▼
$2.31
52-Week Range: $0.69
▼
$26.41

Volume: 29,347 shs
Average Volume: 121,843 shs
Market Capitalization: $1.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get PainReform alerts:

Ad WealthPress

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

That’s exactly how this expert trader plans to trade his #1 ticker for 2024

About PainReform Stock (NASDAQ:PRFX)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRFX Stock News Headlines

April 18, 2024 | globenewswire.com

PainReform Announces Closing of $4 Million Public Offering

April 16, 2024 | finance.yahoo.com

PainReform Announces Pricing of $4 Million Public Offering

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 9, 2024 | msn.com

EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

April 9, 2024 | finance.yahoo.com

PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

April 9, 2024 | globenewswire.com

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

April 4, 2024 | finance.yahoo.com

UK watchdog says Theramex-Viatris deal raises competition concerns

April 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management Market

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

April 2, 2024 | finance.yahoo.com

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

April 2, 2024 | globenewswire.com

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

March 7, 2024 | markets.businessinsider.com

Buy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid Crisis

March 1, 2024 | globenewswire.com

PainReform Provides Year-End Business Update

January 22, 2024 | finance.yahoo.com

PainReform to Present at the Microcap Conference in Atlantic City

January 12, 2024 | msn.com

PainReform files to sell 968,545 ordinary shares for holders

January 5, 2024 | markets.businessinsider.com

Buy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market Advantage

January 3, 2024 | finance.yahoo.com

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

December 26, 2023 | finance.yahoo.com

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

December 19, 2023 | benzinga.com

PainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and Dates

November 19, 2023 | finanznachrichten.de

PainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023

November 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)

November 15, 2023 | finance.yahoo.com

PainReform Provides Business Update for the Third Quarter of 2023

November 12, 2023 | morningstar.com

PainReform Ltd Ordinary Shares PRFX

September 12, 2023 | markets.businessinsider.com

PainReform (PRFX) Gets a Buy from Maxim Group

September 11, 2023 | finance.yahoo.com

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

September 7, 2023 | finance.yahoo.com

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

September 7, 2023 | finance.yahoo.com

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

See More Headlines

Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRFX
CUSIP: N/A
CIK: 1801834
Web: www.painreform.com
Phone: 972-3717-7051
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.07
Quick Ratio: 4.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.65 per share
Price / Book: 0.19

Miscellaneous

Outstanding Shares: 2,030,000
Free Float: 1,329,000
Market Cap: $1.78 million
Optionable: Not Optionable
Beta: 0.53

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Ehud Geller Ph.D.
Executive Chairman
Mr. Ilan Hadar M.B.A. (Age 55)
CEO & CFO
Comp: $404k
Dr. Sigal Aviel (Age 60)
Chief Operating Officer
Comp: $345k
Prof. Eli Hazum Ph.D.
CTO & Director
Ms. Rita Keynan (Age 55)
Vice President of Pharmaceutical Operations
Comp: $302k
Dr. Stephen A. Cooper D.M.D Ph.D.
Executive Vice President of Development

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 170,000 shares on 2/13/2024
Ownership: 10.897%

View All Institutional Transactions

PRFX Stock Analysis - Frequently Asked Questions

How have PRFX shares performed in 2024?: PainReform's stock was trading at $2.75 at the start of the year. Since then, PRFX stock has decreased by 68.1% and is now trading at $0.8780.
View the best growth stocks for 2024 here.
When is PainReform's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PRFX earnings forecast.
How were PainReform's earnings last quarter?: PainReform Ltd. (NASDAQ:PRFX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($1.80) earnings per share for the quarter, beating analysts' consensus estimates of ($4.30) by $2.50.
When did PainReform's stock split?: Shares of PainReform reverse split before market open on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of PainReform own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).
When did PainReform IPO?: PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.
How do I buy shares of PainReform?: Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRFX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial